Return to search results
Avacopan
Tavneos (avacopan) is an oral prescription capsule containing 10 mg of avacopan, manufactured by ChemoCentryx, Inc. It acts as a complement 5a receptor antagonist and cytochrome P450 3A4 inhibitor, approved by the FDA in October 2021 for treating certain inflammatory conditions. Available in bottles of 30 or 180 capsules. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Tavneos (avacopan) is an oral prescription capsule containing 10 mg of avacopan, manufactured by ChemoCentryx, Inc. It acts as a complement 5a receptor antagonist and cytochrome P450 3A4 inhibitor, approved by the FDA in October 2021 for treating certain inflammatory conditions. Available in bottles of 30 or 180 capsules. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Avacopan",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Avacopan — ANDA 214487 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214487"
}
]
|
| identifier | ANDA214487 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-manufacturers",
"drug-safety",
"health-care",
"prescription-drugs"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Avacopan |
